AstraZeneca On Tagrisso's Milestone Advance Into Adjuvant Lung Cancer

Oncology business unit head David Fredrickson talked to Scrip about Tagrisso’s approval as the first targeted adjuvant treatment for patients who have NSCLC with EGFR mutations.

Astrazeneca
AstraZeneca's Tagrisso is approved in adjuvant NSCLC • Source: Shutterstock

AstraZeneca PLC's lung cancer therapy Tagrisso (osimertinib) is the first targeted therapy approved by the US Food and Drug Administration for adjuvant treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, an early setting where treatment could make a substantial impact.

"In a year where good news is sometimes hard to come by, I think that this approval is incredibly great...

More from Anticancer

More from Therapy Areas